A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy

Immune checkpoint inhibitors, such as monoclonal antibodies targeting programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1), have achieved enormous success in the treatment of several cancers. However, monoclonal antibodies are expensive to produce, have poor tumor penetration, and may ind...

Full description

Bibliographic Details
Main Authors: Yuanyuan Wang, Tingxuan Gu, Xueli Tian, Wenwen Li, Ran Zhao, Wenqian Yang, Quanli Gao, Tiepeng Li, Jung-Hyun Shim, Chengjuan Zhang, Kangdong Liu, Mee-Hyun Lee
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Immunology
Subjects:
PD-1/PD-L1 inhibitor 1
PDI-1
PD-1/PD-L1
small molecule compound
immunotherapy
T cell activation
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.654463/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.654463/full

Similar Items